Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Stephan

Showing results (121-130 of 146) with videos related to

Pageof 15
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa FeverVanessa N Raabe, Gerrit Kann, Bruce S Ribner, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 19, 2018
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 StudyJosé M Gatell, Lambert Assoumou, Graeme Moyle, et al.
BMC Infectious Diseases|November 10, 2016
Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint projectNicole Ngo-Giang-Huong, Linda Wittkop, Ali Judd, et al.
AIDS (London, England)|May 31, 2013
Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009Sophie Abgrall, Suzanne M Ingle, Margaret T May, et al.
The Lancet. HIV|March 23, 2023
Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studiesAdam Trickey, Caroline A Sabin, Greer Burkholder, et al.
AIDS (London, England)|May 14, 2024
Care interruptions and mortality among adults in Europe and North AmericaAdam Trickey, Lei Zhang, Christopher T Rentsch, et al.
Infection|July 3, 2020
Treatment modification after starting cART in people living with HIV: retrospective analysis of the German ClinSurv HIV Cohort 2005-2017Melanie Stecher, Philipp Schommers, Christian Kollan, et al.
International Journal of Epidemiology|April 12, 2012
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration, Charlotte Lewden, Vincent Bouteloup, et al.
Frontiers in Immunology|August 1, 2022
Host KIR/HLA-C Genotypes Determine HIV-Mediated Changes of the NK Cell Repertoire and Are Associated With Vpu Sequence Variations Impacting Downmodulation of HLA-CSarah Vollmers, Annabelle Lobermeyer, Annika Niehrs, et al.
The Lancet. Infectious Diseases|March 1, 2011
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort studyLinda Wittkop, Huldrych F Günthard, Frank de Wolf, et al.
Pageof 15

Showing results (121-130 of 146) with videos related to

Sort By:
Pageof 15
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa FeverVanessa N Raabe, Gerrit Kann, Bruce S Ribner, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 19, 2018
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 StudyJosé M Gatell, Lambert Assoumou, Graeme Moyle, et al.
BMC Infectious Diseases|November 10, 2016
Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint projectNicole Ngo-Giang-Huong, Linda Wittkop, Ali Judd, et al.
AIDS (London, England)|May 31, 2013
Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009Sophie Abgrall, Suzanne M Ingle, Margaret T May, et al.
The Lancet. HIV|March 23, 2023
Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studiesAdam Trickey, Caroline A Sabin, Greer Burkholder, et al.
AIDS (London, England)|May 14, 2024
Care interruptions and mortality among adults in Europe and North AmericaAdam Trickey, Lei Zhang, Christopher T Rentsch, et al.
Infection|July 3, 2020
Treatment modification after starting cART in people living with HIV: retrospective analysis of the German ClinSurv HIV Cohort 2005-2017Melanie Stecher, Philipp Schommers, Christian Kollan, et al.
International Journal of Epidemiology|April 12, 2012
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration, Charlotte Lewden, Vincent Bouteloup, et al.
Frontiers in Immunology|August 1, 2022
Host KIR/HLA-C Genotypes Determine HIV-Mediated Changes of the NK Cell Repertoire and Are Associated With Vpu Sequence Variations Impacting Downmodulation of HLA-CSarah Vollmers, Annabelle Lobermeyer, Annika Niehrs, et al.
The Lancet. Infectious Diseases|March 1, 2011
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort studyLinda Wittkop, Huldrych F Günthard, Frank de Wolf, et al.
Pageof 15